Milebot Robotics Raises $9.6M for Medical Exoskeletons

Milebot Robotics, a pioneering Chinese developer of medical exoskeletons, has successfully closed a strategic funding round totaling approximately 100 million yuan (around $9.6 million USD). The investment was led by China Securities, signaling strong confidence in the company's innovative approach to rehabilitation and assistive technologies. This capital infusion is earmarked for accelerating the integration of cutting-edge technology with clinical applications, expanding its product portfolio, and bolstering its international market presence.

Established in 2016, Milebot has distinguished itself as an early mover in the commercialization of medical exoskeletons within China. The company reports a remarkable growth trajectory, with its 2025 performance showing a 200% increase year-over-year. Significantly, international sales now account for over a third of its total revenue, highlighting a successful global expansion strategy.

At the heart of Milebot's technological advantage lies its proprietary flexible actuator system. Unlike traditional rigid exoskeletons that rely heavily on mechanical structures, Milebot's solution integrates biomechanical modeling with rehabilitation training principles. This approach empowers patients to actively participate in their recovery process. Clinical data shared by the company indicates that stroke patients undergoing this specialized training experience approximately a 50% reduction in the time required to regain motor function compared to conventional therapies.

The medical exoskeleton market is experiencing significant growth, driven by an aging global population, increasing incidence of neurological disorders, and advancements in robotics and AI. The global exoskeleton market size was valued at approximately USD 1.5 billion in 2023 and is projected to grow at a CAGR of over 15% in the coming years, with medical applications forming a substantial segment. Milebot's focus on user-centric design and demonstrable clinical outcomes positions it well within this expanding sector.

Milebot currently offers three distinct product lines: lower limb rehabilitation, accessible health management and elder care, and daily walking assistance. Its flagship products have secured regulatory approval from the China National Medical Products Administration (NMPA) as Class II medical devices, enabling mass production and market distribution. The company is also actively exploring the synergy between Brain-Machine Interfaces (BMI) and exoskeleton robotics, aiming to further enhance rehabilitation outcomes through advanced neuro-robotic integration.

This latest funding round underscores the increasing investor appetite for medtech innovations that offer tangible improvements in patient care and quality of life. The strategic investment from China Securities is expected to propel Milebot's next phase of growth, enabling further research and development into next-generation assistive devices and solidifying its position as a key player in the global medical robotics arena.